Interactions between sympathomimetic amines and antidepressant agents in man.
PDF (1014K)
Journal: 1973/April - British Medical Journal
ISSN: 0007-1447
PUBMED: 4685619
Abstract:
Intravenous infusions of phenylephrine, noradrenaline, adrenaline, and isoprenaline were given to healthy human volunteers after five to seven days on phenelzine, tranylcypromine, or imipramine, and cardiovascular responses were compared with those observed under control conditions. With monoamine oxidase inhibitors there was a 2-2(1/2) fold potentiation of the pressor effect of phenylephrine, but no clinically significant potentiation of cardiovascular effects of noradrenaline, adrenaline, or isoprenaline. With imipramine there was potentiation of the pressor effects of phenylephrine (2-3 fold), noradrenaline (4-8 fold), and adrenaline (2-4 fold); there were dysrhythmias during adrenaline infusions, but no noticeable or consistent changes in response to isoprenaline.Noradrenaline and adrenaline in amounts contained in local anaesthetics used in dentistry are not likely to be significantly potentiated in otherwise healthy patients receiving monoamine oxidase inhibitors. Hazardous potentiation of their cardiovascular effects might occur in patients receiving tricyclic antidepressants.Our observations do not indicate that the hazards associated with isoprenaline inhalation by bronchial asthmatics would be increased by coincident therapy with a monoamine oxidase inhibitor or tricyclic antidepressant.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(27)
References
(25)
Conditions
(1)
Drugs
(20)
Chemicals
(3)
Organisms
(1)
Processes
(2)
Anatomy
(1)
Similar articles
Articles by the same authors
Discussion board
Br Med J 1(5849): 311-315
PMID: 4685619

Interactions between Sympathomimetic Amines and Antidepressant Agents in Man

Abstract

Intravenous infusions of phenylephrine, noradrenaline, adrenaline, and isoprenaline were given to healthy human volunteers after five to seven days on phenelzine, tranylcypromine, or imipramine, and cardiovascular responses were compared with those observed under control conditions. With monoamine oxidase inhibitors there was a 2-2½ fold potentiation of the pressor effect of phenylephrine, but no clinically significant potentiation of cardiovascular effects of noradrenaline, adrenaline, or isoprenaline. With imipramine there was potentiation of the pressor effects of phenylephrine (2-3 fold), noradrenaline (4-8 fold), and adrenaline (2-4 fold); there were dysrhythmias during adrenaline infusions, but no noticeable or consistent changes in response to isoprenaline.

Noradrenaline and adrenaline in amounts contained in local anaesthetics used in dentistry are not likely to be significantly potentiated in otherwise healthy patients receiving monoamine oxidase inhibitors. Hazardous potentiation of their cardiovascular effects might occur in patients receiving tricyclic antidepressants.

Our observations do not indicate that the hazards associated with isoprenaline inhalation by bronchial asthmatics would be increased by coincident therapy with a monoamine oxidase inhibitor or tricyclic antidepressant.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1014K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 311
311
icon of scanned page 312
312
icon of scanned page 313
313
icon of scanned page 314
314
icon of scanned page 315
315

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aellig WH, O'Neil R, Laurence DR, Verrill PJ. Cardiac effects of adrenaline and felypressin as vasoconstrictors in local anaesthesia for oral surgery under diazepam sedation. Br J Anaesth. 1970 Feb;42(2):174–176. [PubMed] [Google Scholar]
  • Alexanderson B, Evans DA, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J. 1969 Dec 27;4(5686):764–768.[PMC free article] [PubMed] [Google Scholar]
  • AXELROD J. Metabolism of epinephrine and other sympathomimetic amines. Physiol Rev. 1959 Oct;39:751–776. [PubMed] [Google Scholar]
  • Boakes AJ, Laurence DR, Lovel KW, O'Neil R, Verrill PJ. Adverse reactions to local anaesthetic-vasoconstrictor preparations. A study of the cardiovascular responses to Xylestesin and Hostacain-with-Noradrenaline. Br Dent J. 1972 Aug 15;133(4):137–140. [PubMed] [Google Scholar]
  • Clark B, Thompson JW, Widdrington G. Analysis of the inhibition of pethidine N-demethylation by monoamine oxidase inhibitors and some other drugs with special reference to drug interactions in man. Br J Pharmacol. 1972 Jan;44(1):89–99.[PMC free article] [PubMed] [Google Scholar]
  • Costa E, Boullin DJ, Hammer W, Vogel W, Brodie BB. Interactions of drugs with adrenergic neurons. Pharmacol Rev. 1966 Mar;18(1):577–597. [PubMed] [Google Scholar]
  • Coull DC, Crooks J, Dingwall-Fordyce I, Scott AM, Wier RD. Amitriptyline and cardiac disease. Risk of sudden death identified by monitoring system. Lancet. 1970 Sep 19;2(7673):590–591. [PubMed] [Google Scholar]
  • Cuthbert MF, Vere DW. Potentiation of the cardiovascular effects of some catecholamines by a monoamine oxidase inhibitor. Br J Pharmacol. 1971 Oct;43(2):471P–472P.[PMC free article] [PubMed] [Google Scholar]
  • Cuthbert MF, Greenberg MP, Morley SW. Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J. 1969 Feb 15;1(5641):404–406.[PMC free article] [PubMed] [Google Scholar]
  • EBLE JN. A STUDY OF THE MECHANISMS OF THE MODIFYING ACTIONS OF COCAINE, EPHEDRINE AND IMIPRAMINE ON THE CARDIOVASCULAR RESPONSE TO NOREPINEPHRINE AND EPINEPHRINE. J Pharmacol Exp Ther. 1964 Apr;144:76–82. [PubMed] [Google Scholar]
  • Eble JN, Gowdey CW, Vane JR. Blood concentration of noradrenaline in the dog after intravenous administration and the effects of desipramine. Nature. 1971 May 21;231(5299):181–182. [PubMed] [Google Scholar]
  • Elis J, Laurence DR, Mattie H, Prichard BN. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J. 1967 Apr 8;2(5544):75–78.[PMC free article] [PubMed] [Google Scholar]
  • Fischbach R, Harrer G, Harrer H. Verstärkung der Noradrenalin-Wirkung durch Psychopharmaka beim Menschen. Arzneimittelforschung. 1966 Feb;16(2):263–265. [PubMed] [Google Scholar]
  • HARRER G, HARRER H, FISCHBACH R. DIE BEEINFLUSSUNG PHARMAKODYNAMISCHER KREISLAUFBELASTUNGEN DURCH ANTIDEPRESSIVA. Wien Med Wochenschr. 1964 Oct 17;114:717–726. [PubMed] [Google Scholar]
  • Drug interactions. Drug Ther Bull. 1967 Nov 10;5(23):89–92. [PubMed] [Google Scholar]
  • HORWITZ D, GOLDBERG LI, SJOERDSMA A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitors in man. J Lab Clin Med. 1960 Nov;56:747–753. [PubMed] [Google Scholar]
  • Hunter KR, Boakes AJ, Laurence DR, Stern GM. Monoamine oxidase inhibitors and L-dopa. Br Med J. 1970 Aug 15;3(5719):388–388.[PMC free article] [PubMed] [Google Scholar]
  • Marley E, Blackwell B. Interactions of monoamine oxidase inhibitors, amines, and foodstuffs. Adv Pharmacol Chemother. 1970;8:185–349. [PubMed] [Google Scholar]
  • Moir DC, Cornwell WB, Dingwall-Fordyce I, Crooks J, O'Malley K, Turnbull MJ, Weir RD. Cardiotoxicity of amitriptyline. Lancet. 1972 Sep 16;2(7777):561–564. [PubMed] [Google Scholar]
  • Prescott LF. Pharmacokinetic drug interactions. Lancet. 1969 Dec 6;2(7632):1239–1243. [PubMed] [Google Scholar]
  • Rand MJ, Trinker FR. The mechanism of the augmentation of responses to indirectly acting sympathomimetic amines by monoamine oxidase inhibitors. Br J Pharmacol Chemother. 1968 Jun;33(2):287–303.[PMC free article] [PubMed] [Google Scholar]
  • ROSE GA, HOLLAND WW, CROWLEY EA. A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS. Lancet. 1964 Feb 8;1(7328):296–300. [PubMed] [Google Scholar]
  • SIGG EB, OSBORNE M, KOROL B. CARDIOVASCULAR EFFECTS OF IMIPRAMINE. J Pharmacol Exp Ther. 1963 Aug;141:237–243. [PubMed] [Google Scholar]
  • SPECTOR S. Monoamine oxidase in control of brain serotonin and norepinephrine content. Ann N Y Acad Sci. 1963 Jul 8;107:856–864. [PubMed] [Google Scholar]
  • Svedmyr N. The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man. Life Sci. 1968 Jan 1;7(1):77–84. [PubMed] [Google Scholar]
Copyright notice
Abstract
Intravenous infusions of phenylephrine, noradrenaline, adrenaline, and isoprenaline were given to healthy human volunteers after five to seven days on phenelzine, tranylcypromine, or imipramine, and cardiovascular responses were compared with those observed under control conditions. With monoamine oxidase inhibitors there was a 2-2½ fold potentiation of the pressor effect of phenylephrine, but no clinically significant potentiation of cardiovascular effects of noradrenaline, adrenaline, or isoprenaline. With imipramine there was potentiation of the pressor effects of phenylephrine (2-3 fold), noradrenaline (4-8 fold), and adrenaline (2-4 fold); there were dysrhythmias during adrenaline infusions, but no noticeable or consistent changes in response to isoprenaline.
Noradrenaline and adrenaline in amounts contained in local anaesthetics used in dentistry are not likely to be significantly potentiated in otherwise healthy patients receiving monoamine oxidase inhibitors. Hazardous potentiation of their cardiovascular effects might occur in patients receiving tricyclic antidepressants.
Our observations do not indicate that the hazards associated with isoprenaline inhalation by bronchial asthmatics would be increased by coincident therapy with a monoamine oxidase inhibitor or tricyclic antidepressant.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.